$747 Million is the total value of Broadfin Capital, LLC's 40 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 55.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Sell | SPDR SERIES TRUSTput | $33,289,000 | -37.6% | 350,000 | -50.0% | 4.46% | -54.8% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $22,496,000 | -5.4% | 1,049,244 | -33.1% | 3.01% | -31.5% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $22,284,000 | +0.3% | 409,338 | -23.1% | 2.98% | -27.4% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $18,422,000 | +31.4% | 1,236,368 | -9.6% | 2.47% | -4.8% |
| XENT | Sell | INTERSECT ENT INC | $15,712,000 | +18.6% | 631,023 | -19.0% | 2.10% | -14.1% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $14,762,000 | -28.3% | 533,301 | -52.9% | 1.98% | -48.1% |
| REPH | Sell | RECRO PHARMA INC | $13,217,000 | +20.8% | 721,073 | -27.0% | 1.77% | -12.5% |
| SIEN | Sell | SIENTRA INC | $11,506,000 | -11.3% | 1,286,987 | -35.7% | 1.54% | -35.7% |
| SLGL | Sell | SOL GEL TECHNOLOGIES | $8,949,000 | +76.7% | 521,819 | -7.4% | 1.20% | +28.0% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $7,769,000 | -39.8% | 1,029,012 | -66.8% | 1.04% | -56.4% |
| ZGNX | Sell | ZOGENIX INC | $7,034,000 | +27.3% | 134,937 | -2.2% | 0.94% | -7.8% |
| SSKN | Sell | STRATA SKIN SCIENCES INC | $3,826,000 | -39.0% | 1,839,372 | -36.9% | 0.51% | -55.8% |
| HRTX | Sell | HERON THERAPEUTICS INC | $2,109,000 | +16.1% | 89,730 | -8.7% | 0.28% | -16.1% |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.21% | – |
| HRTX | Exit | HERON THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -0.34% | – |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -505,900 | -100.0% | -0.42% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -30,000 | -100.0% | -0.64% | – |
| SIBN | Exit | SI BONE INC | $0 | – | -223,291 | -100.0% | -0.73% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -1,336,700 | -100.0% | -0.83% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -880,303 | -100.0% | -0.86% | – |
| XGN | Exit | EXAGEN INC | $0 | – | -311,284 | -100.0% | -0.89% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -2,578,003 | -100.0% | -1.14% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -610,414 | -100.0% | -1.31% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -177,016 | -100.0% | -1.59% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -154,500 | -100.0% | -2.16% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -618,500 | -100.0% | -2.36% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -150,510 | -100.0% | -2.39% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -200,000 | -100.0% | -2.88% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -96,504 | -100.0% | -3.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.